Nyheter | Spotlight
Hem

Press release from Companies

Publicerat: 2019-01-11 16:34:37

Panion Animal Health AB: Panion presents at Animal Health Investment Europe, in London 26-27 February 2019

Panion Animal Health AB develops an innovative treatment for epilepsy in dogs and has just started the clinical phase. The product in development is based on the gene therapy platform for human epilepsy from CombiGene AB.

Panion has been selected as one of 24 finalist companies to present at the 2019 Animal Health Investment Innovation Showcase. Panion’s chairman of the board, Lars Thunberg, and CEO, Anja Holm, will address the audience with a focus on the commercial elements of Panion’s business and plans in the programme on translational technology from human-to-veterinary pharma.

The Animal Health Investment Europe is a premier investment forum showcasing the most exciting investment opportunities in animal health and nutrition and connecting those businesses with financial investors and strategic corporate partners. The event is organised by Kisaco Research and supported by the most influential bodies across the Animal Health, Nutrition and Veterinary industries. The showcase arrangement is partnered with the Stonehaven Consulting team.

More information on:

https://www.animalhealthevent.com/events/animal-health-innovation-europe-2019


Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com


Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Läs mer hos Cision
Läs mer om Panion Animal Health AB